Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...

Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in ...

Ozempic and Wegovy, the two brand names under which the company sells the GLP-1 drug semaglutide, are already blockbusters.

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

Health and wellness companies are responding in kind, with recent market developments coming from: PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF), Novo Nordisk A/S (NYSE: NVO), Eli Lilly and Company ...

In July, research presented at the Alzheimer’s Association International Conference found that a GLP-1 drug similar to ...

While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...

Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...

This week, Novo Nordisk, the Copenhagen, Denmark based pharmaceutical company, asked the US Food and Drug Administration (FDA ...

Novo Nordisk is continuing its crusade against compounded versions of its blockbuster weight loss drugs by petitioning the ...

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

In an observational study, Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among ...